China To Fast-Track Approval For Hemophilia Drugs

SHANGHAI - In an effort to combat the domestic shortage of hemophilia treatments, China's State Food and Drug Administration announced Sept. 18 that it will fast track the approval process for Bayer Healthcare's Kogenate FS (recombinant-clotting factor VIII), which has had an application pending at SFDA since last November